871025-06-8

Basic information

• Product Name: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol
• Synonyms: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol;6-(Furan-2-yl)-3H-pyrrolo[3,2-d]pyriMidin-4(5H)-one
• CAS NO: 871025-06-8
• Molecular Formula: C₁₀H₇N₃O₂
• Molecular Weight: 201.18148
• Mol File: 871025-06-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol(871025-06-8)
• EPA Substance Registry System: 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyriMidin-4-ol(871025-06-8)

Safety Data

• Hazardous Substances Data: 871025-06-8(Hazardous Substances Data)

Usage

General Description

6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol, also known as Olaparib, is a chemical compound that belongs to the class of pyrrolopyrimidines. It is a potent inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP) and is commonly used as a targeted therapy for the treatment of certain types of cancer, particularly ovarian and breast cancer. Olaparib works by blocking the PARP enzyme, which plays a role in DNA repair, leading to the accumulation of DNA damage and ultimately inducing cell death in cancer cells. It is commonly administered orally in tablet form and has shown promising results in clinical trials for its ability to improve progression-free survival and overall survival in cancer patients with specific genetic mutations.

Upstream product

• 3473-63-0 formamidine acetic acid 
• 237435-96-0 ethyl 3-amino-5-(2-furanyl)-1H-pyrrole-2-carboxylate 

Downstream Products

• 871025-07-9 4-chloro-6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidine 

Relevant articles and documents

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is -NR 3 -Y 1 -, -O-, -S-, -SO-, -SO 2 or -CHR 3 - wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.